Home » Search results for '2014 survey' (Page 2)
Search Results for: 2014 survey
A recent review article by Ramalho et al summarizes the literature on gadolinium-based contrast agents or GBCAs that are administered for contrast-enhanced MRIs, and it ties together information on agent stability, and animal and human studies. The article, “Gadolinium-Based Contrast Agent Accumulation and Toxicity: An Update”, also emphasizes that the low-stability agents are the ones most often associated with brain deposition of gadolinium that has been reported in the literature since 2014.
Since the article has Open Access at AJNR.org, I will not go into all of the details of it. However, there are some facts contained in the paper that I want to present here that are relevant to why GadoliniumToxicity.com exists. In 2014, Hubbs Grimm and I created this website as a way to alert people to a problem that was not yet recognized by the FDA and medical industry. That problem was gadolinium retention in patients with normal renal function. We knew the facts were in the published literature, but they just had not been seen by the right people yet. Thankfully, that has now begun to change.
Nephrogenic Systemic Fibrosis (NSF)
No review of GBCAs would be complete without some background information on NSF.
In 2006, the association between the administration of GBCAs and the development of Nephrogenic Systemic Fibrosis (NSF) in patients with severe renal disease was reported by Grobner and then by Marckmann et al. NSF predominantly involves the skin, but it is a systemic disease that may also affect other organs such as the lungs, liver, heart, and muscles. The exact pathophysiology of NSF remains unknown, but as the review states, the dissociation of gadolinium ions from their chelating ligands has been accepted as the primary etiology. That is more likely to occur in patients with renal failure than in those with normal renal function since the excretion rate is reduced in those with renal failure. The article indicates that most cases of NSF reported in the literature have been associated with the administration of nonionic, linear gadodiamide (Omniscan, GE Healthcare), nonionic, linear gadoversetamide (OptiMARK, Covidien), and with ionic, linear gadopentetate dimeglumine (Magnevist, Bayer HealthCare Pharmaceuticals).
After limiting the use of GBCAs in patients with renal failure and using more stable GBCAs, there have been no new cases of NSF reported since mid-2009. According to the paper, from 2009 to 2014, confidence in the safety of GBCAs had been largely restored. However, since 2014, numerous studies have been published that reported finding evidence of gadolinium deposition in neural tissues in patients with normal renal function. (more…)
Editorial – I believe the FDA needs to do more to regulate the use of linear and macrocyclic gadolinium-based contrast agents administered for enhanced MRIs and MRAs.
Since January 2014, I am aware of nine studies that have reported finding evidence of gadolinium deposition within the brain tissues of patients exposed to gadolinium-based contrast agents or GBCAs. In most of those studies, the patients did not have severe renal disease, in fact, most were described as having “normal renal function” or an eGFR >60. Despite the increasing number of new studies that indicate that gadolinium is remaining in the brain, some still question whether there is any clinical significance. Speaking as someone who has been adversely affected by retained gadolinium, I believe that there is clinical significance, and I am not alone. Members of our MRI-Gadolinium-Toxicity support group have reported symptoms that are consistent with what is known about the toxic effects of gadolinium. Since we released the results of our 2014 Survey of the Chronic Effects of Retained Gadolinium from Contrast MRIs, our support group has almost tripled in size and another affected patient recently started a group on Facebook. I believe the problems related to gadolinium retention are significant, but they are not being recognized. (more…)
Although it was not known at the time, evidence of a problem related to Gadolinium-Based Contrast Agents (GBCAs) first appeared in 1997 in a group of 15 renal dialysis patients in California. The cases were first described in the literature in 2000 as a scleromyxoedema-like dermopathy that was characterized by thickening and hardening of the skin of the extremities.
Because the disease was thought to be a new fibrosing skin disorder that affected patients with severely impaired renal (kidney) function, it was named Nephrogenic Fibrosing Dermopathy (NFD). The cause was unknown.
The first cases in 1997 were investigated by The Centers for Disease Control and Prevention (CDC) and doctors from the University of California in San Francisco including Dr. Philip LeBoit and Dr. Shawn Cowper. In 2001, Dr. Cowper moved to Yale University School of Medicine and the investigative effort also moved to Yale. Dr. Cowper is currently in charge of confirming and investigating cases of NFD/NSF. He also maintains the NSF Registry which is a repository of information about patients with NSF from around the world.
By 2003, further evaluation including autopsies on deceased NFD patients, found that the damage caused by the disease went far beyond the patients’ skin and involved internal organs and tissues.,, The name was then changed to Nephrogenic Systemic Fibrosis (NSF) to reflect the systemic nature of the disease.
In 2006, Dr. Thomas Grobner of Austria first made the connection between Gadolinium-Based Contrast Agents administered for MRI and the disease currently known as NSF. That same year Dr. Peter Marckmann and colleagues published their study that also confirmed the connection.
Various treatments for NSF have been tried, but none have been consistently successful. While some NSF patients have seen improvement of their skin changes and joint contractures, NSF still remains an incurable and potentially life-threatening disease.
Since 1997, when problems first appeared, much of the research has been focused on trying to determine how and why NSF/NFD happened only in renally-impaired patients. Although NSF is known to be a systemic disease, the diagnosis is still primarily based on skin changes and “visible” evidence of a Gadolinium-related problem in patients with severe kidney disease.,,
Since NSF was first described in the literature, most papers have focused on the skin manifestations of the disease as it was seen in severely renally-impaired patients. Page 14 of a December 8, 2009, FDA Advisory Committee Briefing Document provides information from Cowper et al (2008) regarding skin involvement. Skin lesions are often symmetrical and bilateral, and found to be localized in decreasing order of frequency to the lower extremities (85%), upper extremities (66%), trunk (35%), hands (34%), feet (24%), buttocks (9%), and face (3%).
The clinical diagnostic criteria for NSF include: patterned plaques, joint contractures, “cobblestoning”, marked induration/Peau d’orange, puckering/linear banding, superficial plaques, dermal papules, and scleral plaques. Histologic findings include: increased dermal cellularity, CD34+ cells with tram tracking, thick and thin collagen bundles, preserved elastic fibers, and septal involvement. Osseous metaplasia is a highly specific finding in NSF., Some authors have suggested that osseous metaplasia may represent a late, involuting stage of NSF.
However, even among renally-impaired patients, skin findings are not uniform. NSF has presented as a progressive myopathy or muscular disease, with minimal skin findings, in a patient with acute renal failure. It has been reported that the skin manifestations in the late stages of NSF are different from those seen early in the disease and have a varied presentation.,,
A 2011 Japanese study suggested the occurrence of a non-plaque, late-onset type of NSF in patients who presented with glossy, smooth skin with gradual hardening of the skin. That group’s symptoms were reported to develop after a longer time period since their last exposure to Gadolinium. The authors suggested that the “late-onset of NSF may be explained by the slow release of free Gadolinium from bone stores”. In Japan they generally administer a smaller dosage of the GBCA. If less Gadolinium is being retained, it might explain some of the differences in the clinical manifestations.
Since there are differences seen among renally-impaired patients, it would seem that there might also be differences seen between the renally-impaired and non-renally-impaired if less toxic Gadolinium is retained.
It is also possible that the damage is being done of the inside of the patient and not readily seen with the naked eye regardless of the patient’s level of renal function. (See Background on Gadolinium for more information.)
NSF – It’s not caused by the kidneys.
It is now widely recognized by the medical community and government agencies that retained Gadolinium, and not impaired kidney function, is the primary contributor to the development of NSF.
Rheumatologist Dr. Jonathan Kay suggested that the disease be called Gadolinium-Associated Systemic Fibrosis or GASF, since as he said, “NSF neither originates in the kidney nor is caused by factors originating in the kidney”. It’s the Gadolinium in tissue that seems to drive the fibrosis.
Studies have shown that all GBCAs and Gadolinium Chloride (GdCl3+) stimulate fibroblast proliferation in tissue taken from healthy subjects.,,, (Fibroblasts play a role in the production of connective tissue and fibrosis.) There is a growing body of research that provides evidence of Gadolinium or its toxic effects also being found in bone and tissue of study animals and humans with normal renal function.,,,,,,,,
Since at least 1992, dechelation or separation of the GBCA complex due to transmetallation and acid dissociation was confirmed in animal studies. Human in vivo comparative studies confirmed transmetallation occurs in healthy humans., Other than kidney impairment, researchers have said that transmetallation poses the greatest potential risk for the release of the toxic metal ion from the chelate., (Transmetallation is the displacement of the Gadolinium ion (Gd3+) from the chelate by other metal ions in the body such as zinc, calcium, iron and copper.)
Besides transmetallation, there are other factors that can increase the risk of retaining Gadolinium including in patients with normal kidney function. Those risk factors include acidosis, transient acute kidney injury (AKI), recent surgery, inflammatory events, abnormal vascularity, and compromised blood-brain barrier. Cumulative dosage from multiple contrast MRIs or MRAs is thought to be another risk factor. (See Background on Risk Factors for details.)
In 2007, the FDA requested a “boxed warning” be added to all GBCA product labeling that stated that patients with severe kidney insufficiency were at risk of developing NSF. In 2010, the FDA required that GBCAs carry new warnings on their labels about the risk of NSF. Three GBCAs – Magnevist, Omniscan and Optimark – were described as “inappropriate for use among patients with acute kidney injury or chronic severe kidney disease”. The FDA said that all GBCA labels will emphasize the need to screen patients to detect these types of kidney dysfunction before administration.
Since the FDA instituted the new screening and use guidelines in renally-impaired patients, there have been far fewer new cases of NSF. However, based on the published medical literature and our Self-Study reports, it appears that patients with normal kidney function may also be at risk of retaining Gadolinium and experiencing symptoms of Gadolinium Toxicity.
The urine test results presented in our Self-Study of Retained Gadolinium and Appendix 1 of the Symptom Survey Report show patients with no history of kidney problems excreted elevated urine levels of Gadolinium for extended periods of time after their last dose of a GBCA. Based on the published literature, that should not happen to patients with normal kidney function (meaning eGFR >60).
To our knowledge, there are no published cases of biopsy-confirmed NSF in patients with normal kidney function, but that does not mean that Gadolinium-related health issues cannot occur in those patients. Since residual Gadolinium from GBCAs has been found in bone and other tissue of study animals that did not have NSF-like skin lesions,,,, it would seem that patients might not always present clinically with visible evidence of a problem. Currently, there are no established criteria to evaluate patients for other signs of Gadolinium Toxicity beyond the skin changes associated with NSF. That could result in the underreporting of Gadolinium-related health issues in all populations of patients.
While there appear to be many unanswered questions related to Gadolinium-Based Contrast Agents, what is known from the literature is that Gadolinium is toxic to humans and published studies have found evidence of Gadolinium in brain, bone and skin tissues of patients without severe kidney disease.,,,,
Anyone who has unexplained symptoms that they believe were caused by retained Gadolinium from a contrast MRI or MRA should report it to the FDA by filing a MedWatch Adverse Event Report. Call 1-800-FDA-1088 or report via the FDA website at http://www.fda.gov/Safety/MedWatch/HowToReport/default.htm
It is important that Adverse Event Reports related to Gadolinium-Based Contrast Agents are filed with the FDA or the full scope of Gadolinium-related health problems may never be brought to light.
Patients outside the U.S. report to their country’s equivalent governing agency.
 Cowper, S. E., Robin, H. S., Steinberg, S. M., Su, L. D., Gupta, S., & LeBoit, P. E. (2000). Scleromyxoedema-like cutaneous diseases in renal-dialysis patients. Lancet, 356(9234), 1000–1. doi:10.1016/S0140-6736(00)02694-5. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11041404
 Cowper, S. E., Su, L. D., Bhawan, J., Robin, H. S., & LeBoit, P. E. (2001). Nephrogenic fibrosing dermopathy. The American Journal of Dermatopathology, 23(5), 383–93. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/11801769
 Ting, W. W., Stone, M. S., Madison, K. C., & Kurtz, K. (2003). Nephrogenic fibrosing dermopathy with systemic involvement. Archives of Dermatology, 139(7), 903–6. Retrieved from http://archderm.jamanetwork.com/article.aspx?articleid=479394
 Levine, J. M., Taylor, R. A., Elman, L. B., Bird, S. J., Lavi, E., Stolzenberg, E. D., McGarvey, M. L., et al. (2004). Involvement of skeletal muscle in dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy). Muscle & nerve, 30(5), 569–77. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15389718
 Daram, S. R., Cortese, C. M., & Bastani, B. (2005). Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis: report of a new case with literature review. American Journal of Kidney Diseases : the official journal of the National Kidney Foundation, 46(4), 754–9. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16183432
 Grobner, T. (2006). Gadolinium–a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrology, dialysis, transplantation : Official Publication of the European Dialysis and Transplant Association – European Renal Association, 21(4), 1104–8. Retrieved from http://ndt.oxfordjournals.org
 Marckmann, P., Skov, L., Rossen, K., Dupont, A., Damholt, M. B., Heaf, J. G., & Thomsen, H. S. (2006). Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. Journal of the American Society of Nephrology : JASN, 17(9), 2359–62. Retrieved from http://jasn.asnjournals.org/content/17/9/2359.abstract?ijkey=0b63481bca498ae67d9dacce23b4199a49c7dba9&keytype2=tf_ipsecsha
 Basak, P., & Jesmajian, S. (2011). Nephrogenic systemic fibrosis: current concepts. Indian journal of dermatology, 56(1), 59–64. doi:10.4103/0019-5154.77555. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3088938/
 Anon. (2011). Roentgen Ray Reader: New Proposed Criteria for Diagnosis of Nephrogenic Systemic Fibrosis. Retrieved October 5, 2012, from http://roentgenrayreader.blogspot.com/2011/10/new-proposed-criteria-for-diagnosis-of_14.html
 Girardi, M., Kay, J., Elston, D. M., Leboit, P. E., Abu-Alfa, A., & Cowper, S. E. (2011). Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. Journal of the American Academy of Dermatology, 65(6), 1095–1106.e7. http://dx.doi.org/10.1016/j.jaad.2010.08.041
 FDA Advisory Committees. (2009). Gadolinium-Based Contrast Agents & Nephrogenic Systemic Fibrosis – FDA Briefing Document – Advisory Committee December 8, 2009. (UCM190850.pdf). Retrieved August 2, 2012, from http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM190850.pdf
 Cowper, S. E., Rabach, M., & Girardi, M. (2008). Clinical and histological findings in nephrogenic systemic fibrosis. European journal of radiology, 66(2), 191–9. doi:10.1016/j.ejrad.2008.01.016. Retrieved from http://www.sciencedirect.com/science/article/pii/S0720048X08000363
 Girardi, M., Kay, J., Elston, D. M., Leboit, P. E., Abu-Alfa, A., & Cowper, S. E. (2011). Nephrogenic systemic fibrosis: clinicopathological definition and workup recommendations. Journal of the American Academy of Dermatology, 65(6), 1095–1106.e7. doi:10.1016/j.jaad.2010.08.041. Retrieved from http://www.sciencedirect.com/science/article/pii/S0190962210021468
 Anon. (2011). Roentgen Ray Reader Blogspot: New Proposed Criteria for Diagnosis of Nephrogenic Systemic Fibrosis. Retrieved October 5, 2012, from http://roentgenrayreader.blogspot.com/2011/10/new-proposed-criteria-for-diagnosis-of_14.html
 Wiedemeyer, K., Kutzner, H., Abraham, J. L., Thakral, C., Carlson, J. A., Tran, T. A., Hausser, I., et al. (2009). The evolution of osseous metaplasia in localized cutaneous nephrogenic systemic fibrosis: a case report. The American Journal of dermatopathology, 31(7), 674–81. doi:10.1097/DAD.0b013e3181a1fb55. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19633532
 Edgar, E., Woltjer, R., Whitham, R., Gultekin, S. H., Watnick, S., & Cupler, E. J. (2010). Nephrogenic systemic fibrosis presenting as myopathy: a case report with histopathologic correlation. Neuromuscular Disorders : NMD, 20(6), 411–3. Retrieved from http://www.nmd-journal.com/article/S0960-8966(10)00166-5/abstract
 Bangsgaard, N., Marckmann, P., Rossen, K., & Skov, L. (2009). Nephrogenic systemic fibrosis: late skin manifestations. Archives of Dermatology, 145(2), 183–7. Retrieved from http://archderm.jamanetwork.com/article.aspx?articleid=711897
 Girardi, M. (2008). Nephrogenic systemic fibrosis: a dermatologist’s perspective. Journal of the American College of Radiology : JACR, 5(1), 40–4. doi:10.1016/j.jacr.2007.08.017. Retrieved from http://www.jacr.org/article/S1546-1440%252807%252900452-8/abstract
 Boyd, A. S., Zic, J. A., & Abraham, J. L. (2006). Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol. Retrieved September 15, 2012, from http://www.pkdiet.com/pdf/Img gadolinium NFD.pdf
 Matsumoto, Y., Mitsuhashi, Y., Monma, F., Kawaguchi, M., Suzuki, T., Miyabe, C., Igarashi, A., et al. (2012). Nephrogenic systemic fibrosis: a case report and review on Japanese patients. The Journal of dermatology, 39(5), 449–53. Retrieved from http://onlinelibrary.wiley.com/doi/10.1111/j.1346-8138.2011.01407.x/abstract;jsessionid=3818F38119A25ED3F47BB852C85B194F.f01t02
 Kay, J., & Czirjak, L. (2010). Gadolinium and systemic fibrosis: guilt by association. Annals of the Rheumatic Diseases, 69(11), 1895–1897. Retrieved from http://ard.bmj.com/content/69/11/1895.full.pdf
 Kay, J. (2008). Gadolinium and Nephrogenic Systemic Fibrosis: The evidence of things not seen. (editorial). Cleveland Clinic Journal of Medicine, 75(2), 112–117. Retrieved from http://www.ccjm.org/content/75/2/112.full.pdf
 Bhagavathula, N., Dame, M. K., DaSilva, M., Jenkins, W., Aslam, M. N., Perone, P., & Varani, J. (2010). Fibroblast response to gadolinium: role for platelet-derived growth factor receptor. Investigative Radiology, 45(12), 769–77. Retrieved from http://ukpmc.ac.uk/articles/PMC3164279/?report=abstract
 Piera-Velazquez, S., Louneva, N., Fertala, J., Wermuth, P. J., Del Galdo, F., & Jimenez, S. A. (2010). Persistent activation of dermal fibroblasts from patients with gadolinium-associated nephrogenic systemic fibrosis. Annals of the Rheumatic Diseases, 69(11), 2017–23. Retrieved from http://ard.bmj.com/cgi/content/abstract/69/11/2017
 Edward, M., Quinn, J. A., Burden, A. D., Newton, B. B., & Jardine, A. G. (2010). Effect of different classes of gadolinium-based contrast agents on control and nephrogenic systemic fibrosis-derived fibroblast proliferation. Radiology, 256(3), 735–43. Retrieved from http://radiology.rsna.org/content/256/3/735.full
 Bleavins, K., Perone, P., Naik, M., Rehman, M., Aslam, M. N., Dame, M. K., Meshinchi, S., et al. (2012). Stimulation of fibroblast proliferation by insoluble gadolinium salts. Biological trace element research, 145(2), 257–67. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3273605/pdf/nihms331598.pdf
 Tweedle, M. F. (1992). Physicochemical Properties of Gadoteridol and Other Magnetic Resonance Contrast Agents. Investigative Radiology. Retrieved October 21, 2012, from http://www.ph.braccosolutions.com/Shared Documents/Tweedle Physicochemical_Properties_of_Gadoteridol_and.2.pdf
 Harpur, E. S., & et. (1993). Preclinical Safety Assessment and Pharmacokinetics of Gadodiamide Injection, a New Magnetic Resonance Imaging Contrast Agent. Investigative Radiology, 28(Supplement 1), S28–S43. Retrieved from http://gehc.s3.amazonaws.com/presskits/Omniscan+Denmark/Bilag+7+%28Harpur+et+al.%29.pdf
 Pietsch, H., Lengsfeld, P., Jost, G., Frenzel, T., Hütter, J., & Sieber, M. A. (2009). Long-term retention of gadolinium in the skin of rodents following the administration of gadolinium-based contrast agents. European Radiology, 19(6), 1417–24. Retrieved from http://www.springerlink.com/content/30g331p7p8438w21/
 Aime, S., & Caravan, P. (2009). Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. Journal of Magnetic Resonance Imaging, 30(6), 1259–1267. Retrieved from http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2822463&tool=pmcentrez&rendertype=abstract
 Pietsch, H., Raschke, M., Ellinger-Ziegelbauer, H., Jost, G., Walter, J., Frenzel, T., Lenhard, D., et al. (2011). The role of residual gadolinium in the induction of nephrogenic systemic fibrosis-like skin lesions in rats. Investigative Radiology, 46(1), 48–56. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20938346
 Wadas, T. J., Sherman, C. D., Miner, J. H., Duncan, J. R., & Anderson, C. J. (2010). The biodistribution of [153Gd]Gd-labeled magnetic resonance contrast agents in a transgenic mouse model of renal failure differs greatly from control mice. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine, 64(5), 1274–80. Retrieved from http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3180881/
 Fulciniti, M., et al, & Dana Farber Cancer Institute Harvard Medical School. (2009). Gadolinium Containig Contrast Agent Promotes Multiple Myeloma Cell Growth: Implications for Clinical Use of MRI in Myeloma (poster presentation). Retrieved from http://myeloma.org/pdfs/ASH2009_Fulciniti_1809.pdf
 Xia, D., Davis, R. L., Crawford, J. A., & Abraham, J. L. (2010). Gadolinium released from MR contrast agents is deposited in brain tumors: in situ demonstration using scanning electron microscopy with energy dispersive X-ray spectroscopy. Acta Radiologica (Stockholm, Sweden : 1987), 51(10), 1126–36. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20868305
 Christensen, K. N., Lee, C. U., Hanley, M. M., Leung, N., Moyer, T. P., & Pittelkow, M. R. (2011). Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. Journal of the American Academy of Dermatology, 64(1), 91–6. Retrieved from http://www.jaad.org/article/S0190-9622%2809%2902325-1/fulltext
 Wedeking, P., Kumar, K., & Tweedle, M. F. (1992). Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. Magnetic resonance imaging, 10(4), 641–8. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/1501535
 Puttagunta, N. R., Gibby, W. A., & Smith, G. T. (1996). Human in vivo comparative study of zinc and copper transmetallation after administration of magnetic resonance imaging contrast agents. Investigative Radiology, 31(12), 739–42. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/8970874
 Kimura, J., Ishiguchi, T., Matsuda, J., Ohno, R., Nakamura, A., Kamei, S., Ohno, K., et al. (2005). Human comparative study of zinc and copper excretion via urine after administration of magnetic resonance imaging contrast agents. Radiation Medicine, 23(5), 322–6. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16342903
 Cacheris, W. P., Quay, S. C., & Rocklage, S. M. (1990). The relationship between thermodynamics and the toxicity of gadolinium complexes. Magnetic Resonance Imaging, 8(4), 467–481. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/2118207
 Rocklage, S. M., Worah, D., & Kim, S.-H. (1991). Metal ion release from paramagnetic chelates: What is tolerable? Magnetic Resonance in Medicine, 22(2), 216–221. doi:10.1002/mrm.1910220211. Retrieved from http://onlinelibrary.wiley.com/doi/10.1002/mrm.1910220211/abstract
 Office of the Commissioner. (2007). 2007 – FDA Requests Boxed Warning for Contrast Agents Used to Improve MRI Images. UCM108919. Office of the Commissioner. Retrieved October 8, 2012, from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108919
 U.S. Food & Drug Administration. (2010). Press Announcements – FDA: New warnings required on use of gadolinium-based contrast agents. UCM225286. Retrieved October 12, 2012, from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225286.htm
 Sieber, M. A., Pietsch, H., Walter, J., Haider, W., Frenzel, T., & Weinmann, H.-J. (2008). A Preclinical Study to Investigate the Development of Nephrogenic Systemic Fibrosis: A Possible Role for Gadolinium-Based Contrast Media. Investigative Radiology, 43(1). Retrieved from http://journals.lww.com/investigativeradiology/Fulltext/2008/01000/A_Preclinical_Study_to_Investigate_the_Development.9.aspx
 Sieber, M. A., Lengsfeld, P., Frenzel, T., Golfier, S., Schmitt-Willich, H., Siegmund, F., Walter, J., et al. (2008). Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. European Radiology, 18(10), 2164–73. Retrieved from http://www.springerlink.com/content/1615m2x5700806k4/
 Pietsch, H., Pering, C., Lengsfeld, P., Walter, J., Steger-Hartmann, T., Golfier, S., Frenzel, T., et al. (2009). Evaluating the role of zinc in the occurrence of fibrosis of the skin: a preclinical study. Journal of magnetic resonance imaging : JMRI, 30(2), 374–83. DOI: 10.1002/jmri.21845. Abstract retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19629978
 Haylor, J., Dencausse, A., Vickers, M., Nutter, F., Jestin, G., Slater, D., Idee, J.-M., et al. (2010). Nephrogenic gadolinium biodistribution and skin cellularity following a single injection of Omniscan in the rat. Investigative Radiology, 45(9), 507–12. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/20697223
 Gibby, W. A., Gibby, K. A., & Gibby, W. A. (2004). Comparison of Gd DTPA-BMA (Omniscan) versus Gd HP-DO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Investigative Radiology, 39(3), 138–42. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15076005
 Darrah, T. H., Prutsman-Pfeiffer, J. J., Poreda, R. J., Ellen Campbell, M., Hauschka, P. V, & Hannigan, R. E. (2009). Incorporation of excess gadolinium into human bone from medical contrast agents. Metallomics : integrated biometal science, 1(6), 479–88. Retrieved from http://pubs.rsc.org/en/content/articlehtml/2009/mt/b905145g
 Kanda, T., Ishii, K., Kawaguchi, H., Kitajima, K., & Takenaka, D. (2013). High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1-weighted MR Images: Relationship with Increasing Cumulative Dose of a Gadolinium-based Contrast Material. Radiology, 131669. doi:10.1148/radiol.13131669. Retrieved from http://pubs.rsna.org/doi/abs/10.1148/radiol.13131669